Small molecule inhibitors selective for polo-like kinase protein

Patent metadata

Field	Value
Publication number	US-12415822-B2
Application number	US-202318106543-A
Country	US
Kind code	B2
Filing date	Feb 7, 2023
Priority date	Apr 5, 2016
Publication date	Sep 16, 2025
Grant date	Sep 16, 2025

Abstract

Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure ofFor instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.

First claim

What is claimed is:

1. A method for inhibiting Polo-like Kinase proteins, the method comprising:
providing a small molecule PLK inhibitor to a medium containing one or more Polo-like Kinase proteins, wherein the small molecule PLK inhibitor has the following structure:

wherein
R 1 comprises an alkyl, —O-alkyl, —S-alkyl, or —NH-alkyl, and optionally includes a terminal aryl;
R 7 is selected from:

2. The method of claim 1 , wherein the medium comprises a solution.

3. The method of claim 1 , wherein the medium comprises one or more cells.

4. The method of claim 1 , wherein the medium comprises one or more cells and the inhibitor induces apoptosis in a least a portion of the one or more cells.

5. The method of claim 1 , wherein the one or more Polo-like Kinase proteins comprise PLK1.

6. The method of claim 1 , wherein the one or more Polo-like Kinase proteins comprise PLK3.

7. The method of claim 3 , wherein the one or more cells comprise HeLa cervical cancer cells, PTEN-deficient prostate cancer (PC3) cells, KRAS mutant lung cancer (A-549) cells, or a combination thereof.

8. The method of claim 1 , wherein R 1 comprises a C10 to C12 alkyl.

9. The method of claim 1 , wherein the small molecule PLK inhibitor has an atomic mass of about 1000 Daltons or less.

10. The method of claim 1 , wherein the small molecule PLK inhibitor has an atomic mass of about 500 Daltons or less.

11. The method of claim 1 , wherein the small molecule PLK inhibitor has a polar surface area of about 200 Å or less.

12. The method of claim 1 , wherein the small molecule PLK inhibitor has a polar surface area of about 100 Å or less.

13. A method for inhibiting Polo-like Kinase proteins, the method comprising:
providing a small molecule PLK inhibitor to a medium containing one or more Polo-like Kinase proteins, wherein the small molecule PLK inhibitor has the structure of one or more of:

Assignees

• Univ South Carolina

Inventors

• Mcinnes Campbell
• Craig Sandra Navonne

Classifications

• A61K31/196

  the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title

• A61K31/167

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• C07C233/80

  with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring · CPC title